

dependent influx of Ca^{++} into the β -cells. Similar effects were reported by Liu et al. (29) where aqueous alcoholic extract (0.06-0.25 mg/ml conc.) secreted insulin from MIN6 β -cell line. Higher concentration (> 0.5 mg/ml) causes increased trypan blue uptake and increases β -cell Ca^{++} levels. The methanolic extract of *Gymnema sylvestre* leaf and callus also exhibits the antidiabetic activities through regeneration of β -cells (30). The green compact callus obtained through *in-vitro* culture exposed to stressful circumstances of exposure to blue light with 2, 4-D (1.5 mg/L) and KN (0.5 mg/L) also showed a significant β -cell regeneration. Sujin et al. in 2008 reported that administration of higher doses (5, 10, 15, 20/g/25 days) of *Gymnema sylvestre* did not show significant mortality but behavioral changes were observed *viz.* lethargic movements and suppression of appetite were observed upon 5 g and 20 g dose (31). *Gymnema sylvestre* is known to suppress the taste stimulus in taste buds. A compound isolated from the searing aqueous excerpt of the *Gymnema sylvestre* leaves was seen to condense the neural response of the murine chorda tympani towards sucrose and this matter was confirmed to be the peptide named Gurmarin which comprised of 35 amino acids of 4,000 Dalton molecular mass. The forestalling potential of the peptide on the sweet perception was established by exposing the tongue with above 1×10^{-6} M of the peptide (32). The inhibitory effect of gurmarin differs among tongue regions and mouse strains (33). A study conducted on the taste perception of rats towards gurmarin revealed that the apex of the tongue is activated upon consumption mostly due to the binding of gurmarin to the receptor protein responsible for the sweet taste perception (34).

The pharmacokinetic and pharmacodynamic interaction was studied by Kamble's colleagues in diabetic rats after concomitant treatment with 400 mg/kg of *Gymnema sylvestre* extract and 0.8 mg/kg of glimepiride drug for four weeks (35). The results revealed a beneficial pharmacodynamic interaction with a significant increase in anti-hyperglycemic activities with no major alterations in the pharmacokinetic parameters. The chitosan nanoparticle with *Gymnema sylvestre* extract was also evaluated against rats induced with streptozotocin and was found to decrease the fasting glucose level and glycosylated hemoglobin at the dose of 100 mg/kg body weight of the rats (36).

Phytochemistry and Bioactive components having anti-diabetic property

The principle component of *Gymnema sylvestre* is gymnemic acid, a complex mixture of at least 17 different saponins (37) mostly oleanane (38) and dammarene classes (39). The longispinogenin 3-O- β -D-glucuronopyranoside, 3-O- β -D-glucopyranosyl (1-6)- β -D-glucopyranosyloleanolic acid 28-O- β -D-glucopyranosylester, 21 β -benzoylsitakisogenin 3-O- β -D-glucuronopyranoside 3-O- β -D-xylopyranosyl (1-6)- β -D-glucopyranosyl (1-6)- β -D-glucopyranosyl oleanolic acid 28-O- β -D-glucopyranosyl ester, oleanolic acid 3-O- β -D-xylopyranosyl(1-6)- β -D-glucopyranosyl(1-6)- β -D-glucopyranoside and 3-O- β -D-glucopyranosyl (1-6)- β -D-glucopyranosyl oleanolic acid 28- β -D-glucopyranosyl (1-6)- β -D-glucopyranosyl ester are the oleanane-triterpene glycosides. These have been unraveled by hydrolysis followed by spectrophotometric analysis. Correspondingly, 7 other novel dammarane-style saponins, extracted from the leaf excerpt of *Gymnema sylvestre*, these are the gymnemasides I-VII. The same category saponins that were known earlier are gypenoside XXVIII, XXXVII, LV, LX11 and LXIII.

The saponin components responsible for the anti-hyperglycemic effect of *Gymnema sylvestre* are gymnemosides and gymnemic acid (40). The consumption of glucose by muscles is prevented by the triterpene glycosides fraction of the plant (41, 42). The inhibitory effects of triterpene glycosides and various gymnemosides from *Gymnema sylvestre* were found to inhibit glucose uptake in rat (43). A novel compound named dihydroxy gymnemic triacetate isolated from acetone extract reduced the blood sugar level by 65% and glycosylated hemoglobin by 39.56% and an increased in plasma insulin level by 63% at 20 mg/kg dose (44). The administration of gymnemic acid IV lowered the sugar level (13.5 mg/kg body weight) to 60%, which was similar to the efficiency of glibenclamide (14.8 mg/kg body weight) (45). Recently, the crystallographic analysis of gymnemagenin indicated its good gelling with the target protein's crystallographic constitution (dipeptidyl peptidases, aldose reductase, glucokinase, fructose 1,6-bisphosphate, cytochrome 450, 11 β -hydroxysteroid dehydrogenase, tyrosine

phosphatases, protein kinase B, glutamine fructose-6-phosphate amidotransferase, Insulin receptor substrate, Glucose transporter, AMP-activated protein kinase, cholesteryl ester transfer protein) having a key responsibility in the carbohydrate regulation (46).

Antihyperlipidemic activity

Diabetes mellitus is often associated with disturbances in lipid metabolism regulating in levels of lipoproteins (47). The lipoprotein abnormalities cause insulin resistance through different factors which may alleviate lipoprotein lipase (LPL) and peroxisome-proliferator activated receptor (PPAR) gamma, on contrary by elevating acyl-CoA synthetase and transporter of microsomal triglyceride. The administration of 25-100 mg/kg dose of the leaf extract of *Gymnema sylvestre* showed a tectonic decline in the lipid profile in a dose reliant approach when administered orally for two weeks in experimental rats. The extract (at 100 mg/kg) of *Gymnema sylvestre* lowers the serum triglyceride, total cholesterol and atherosclerotic property which was almost comparable to a standard lipid-lowering agent (48).

The hypolipidemic activity of higher dose of aqueous leaf extract (up to 800 mg/kg body weight for 30 days) was examined by Mall et al. in alloxan induced diabetic rats (49). The reduction was examined at all doses (400,600 and 800 mg/kg body weight) but the highest concentration was substantial compared to all observed days. While the administration of the excerpt indicated a consequential diminution in the serum lipids and the fasting blood glucose level, it has also shown proof of desirable increase in the serum high-density lipoprotein (HDL)-cholesterol. Similar considerable dwindle in the other lipid parameters and a significant increase ($p < 0.05$) in HDL level was obtained by Rachh et al. in 2010 when hydroalcoholic leaf extract (200 mg/kg body weight) of the plant was administered in the diet of high cholesterol-fed (2% cholesterol + 1% sodium cholate + 2% coconut oil) rats (12).

Gymnema sylvestre when mixed with chitosan and ascorbic acid (1:10:2), possesses protective effects against hypercholesterolemia. Significant decrease in serum triglyceride (35.87%), total cholesterol (43.89%), LDL (54.00%), and atherogenic index (AI) (41.47%), was observed at dose of 4.68 g/kg diet (50). Leaf extract consumption in rats was also seen to re-

duce the noticeable digestion of fat and kick off the emission of neutral sterols and acidic steroids (51). A novel dihydroxy gymnemic triacetate caused a reduction in total cholesterol, triglyceride, LDL by 54%, 55%, and 40% respectively and simultaneously increase in HDL level was 38% observed (44).

Anti-Obese Activity

Abdominal fat deposition is yet another pivotal criterion branded as the harbinger of diabetes. The increase in adipocytes lessens the quantity of insulin receptors on cells that are targets of insulin in our body. This substantially diminishes the requisite amount of insulin to be present in the circulation and potentially reduces its metabolic functions. An alarming 40-80 percentile of diabetics have been reported to be obese. The adipocytes secrete resistin hormone, a 12.5 kDa cysteine-rich protein (52). Studies in murine models have implicated that the prevalence of resistin in the blood circulation accentuates insulin resistance development. Recent *in vivo* and *in vitro* investigations have shown that resistin sways glucose metabolism. In murine models, the inclusion of resistin patently amplifies the creation of glucose from the liver and thus drops the hepatic insulin exploit (53). Pravenec and co-workers (2003) have shown that genetically modified rats which secrete more resistin than required have glucose intolerance and disrupted skeletal muscle glucose metabolism (54).

Gymnema sylvestre is shown to have very useful properties for the management of both obesity and diabetes. Administration of a supplement comprising of *Gymnema sylvestre* with glucomannan, fenugreek, vitamin C and chitosan to a patient with body mass index 30 kg/m² or more resulted in significant reduction in their weight and also the overall fat percentage.

Administration of gymnemic acid increased the fecal excretion of steroids and cholesterol (55). Weight gain was eventually curbed in rats treated with the extract (56). The hexane extract of *Gymnema sylvestre* leaves (150 mg/kg and 250 mg/kg body weight) significantly ($p < 0.001$) reduced increased body weight in Sprague dawley rats (13). A separate study was undertaken to analyze the effect of a new extract of an immensely bio-available, calcium-potassium salt of (-)-hydroxycitric acid for weight loss. The same ex-

cerpt was also used along with a niacin-bound chromium compound and with *Gymnema sylvestre* extract achieved weight loss in mildly fat individuals. Weight loss was analyzed by evaluating body weight fluctuations, body mass index, appetite, serum triglyceride, total cholesterol, HDL, LDL, leptin and serotonin concentrations, the elimination of urinary fat metabolites was also noted (57). *Gymnema sylvestre* extract endorses weight loss as it trims down sweet cravings and thus manages the blood sugar concentrations.

Anti-Oxidant Activity

Oxidative stress is produced under diabetic conditions which are responsible for the development of secondary complications. Reactive oxygen species (ROS) are produced under such conditions through glycation reaction which occurs in various tissues and plays a deleterious role in the diabetic secondary complications (58). The insinuation of oxidative stress in worsening diabetes has been proved by further generation of free radicals, non-enzymatic protein glycosylation, glucose auto-oxidation, alterations of antioxidant enzymes and increase in lipid peroxidation (59).

Antioxidants are effective in reducing diabetic complications. Numerous researchers have professed the healing of insulin resistance in type 2 diabetics and cardiovascular disease patients after the administration of antioxidants such as vitamin C, glutathione and vitamin E. The alcoholic extract of *Gymnema sylvestre* has been seen to restrict the 1, 1-Diphenyl-2-picrylhydrazyl (DPPH) and clear up superoxide and hydrogen peroxide. This ability to reduce radicals has also been exhibited in the ferric reducing prototype wherein the antioxidant capability was 17.54 mg/g expressed in terms of ascorbic acid (14). A noteworthy decline (19.27%) ($p < 0.05$) in the plasma alanine aminotransferase potentiality was obtained by administration of a mixture (4.68 g/kg diet) of chitosan, vitamin C and *Gymnema sylvestre* (10:2:1) (50).

Immunomodulatory Activities

Several components of the immune system face discrepancies when inflicted with type 2 diabetes which lead to inflammation and glucose abnormalities. The cytokines are produced when the macrophages enter the adipocytes; these cytokines specifically cause

the neighboring liver, muscle or fat cells to become insulin resistant. Several markers of inflammation such as C-reactive protein, fibrinogen, the interleukins and tumor necrosis factor- α (60) get elevated in diabetes.

The extracts of *Gymnema sylvestre* restricted the histamine release *in vitro* (21). The leaf extract had significantly elevated the neutrophil chemotaxis that consequentially elevated neutrophils reduction of Nitro Blue Tetrazolium dye to form formazan thus ascertaining intracellular carnage aspect and a total increase in metabolic activity of phagocytosing neutrophils. This is perhaps due to the presence of tannins present in *Gymnema* leaves which have anti-inflammatory and immunomodulatory attributes (16). The methanolic extract of *Gymnema sylvestre* leaves showed a potential effect at 100 μ g/ml in nitric oxide and ROS generation in macrophage and 20 μ g/ml in lymphocyte proliferation leading to stimulation of myeloid and lymphoid elements of the immune system and thereby restoring the innate immunity (61).

Wound Healing Activity

Diabetes exponentially reduces the wound healing capacity of the body, hence the recurrence of a severe, never-healing infection from a simple wound is always a major threat (18). In one of the recent studies, Carbopol gel was prepared from the hydroalcoholic extracts of *Gymnema sylvestre* and *Tagetes erecta* Linn. to determine its wound healing activity in albino mice (62). In both, the models, a prominent decrease in the time required for the occurrence of epithelial tissues was evidently noticed and the combined gel exhibited hastening of the wound healing process. The hydro alcoholic extracts could possibly accentuate wound healing as they have antioxidant potential and the phyto-constituent (flavonoids) prevalent in it that fastens the process of wound healing.

Clinical Studies and Trials on Humans

Gymnema sylvestre is shown to be an effective antidiabetic agent in the clinical trials. The insulinotropic activity of *Gymnema sylvestre* was observed in adult human subjects (25-40 year age group) by administering the 2 g/day in two doses (25). A water based excerpt

of *Gymnema sylvestre* leaves when administered at a dosage of 2 gm thrice daily to 10 normal individuals over a period of ten days and in 6 diabetics for fifteen days potentially lowered the fasting and oral glucose tolerance test (OGTT) glucose intensity barring the OGTT in the normal cluster (63). Quotidian administration of 400 mg leaf excerpt of *Gymnema sylvestre* twice has been observed to diminish the glycosylated hemoglobin (HbA1C) concentration in diabetics (64).

The universal applicability of the *Gymnema sylvestre* in diabetes with either type 1 or type 2 has been established by various studies. In one of the studies, the efficacy of quotidian consumption of 400 mg GS4 was examined on 22 type 2 diabetes patients (65). *Gymnema sylvestre* was seen to radically shrank plasma glucose ($p < 0.001$), HbA1c ($p < 0.001$), and glycosylated plasma protein (GPP) levels during the 18–20-month of valuation time. In another individual study, the efficacy of the *Gymnema sylvestre* excerpt on 27 type 1 diabetics was investigated for 6–30 months (66). It was observed that *Gymnema sylvestre* drastically diminished the GPP levels in the initial six to eight months, and then reduced serum amylase ($p < 0.001$) within 16–18 months. As compared with insulin therapy ($n = 37$), *Gymnema sylvestre* appreciably boosted serum C-peptide concentration in 16–18 months' time ($p < 0.001$). The outcome of the administration of the leaf powder of *Gymnema sylvestre* on plasma glucose concentration of 20 type 2 diabetic women aged between 40–60 years living in Udaipur, Rajasthan was studied by Paliwal et al. in 2009 (67). Everyday 6 gm of *Gymnema sylvestre* leaf powder was given to the subjects in three divided doses and dietary survey using 24 hours recall method was also adopted. Results of intervention revealed that the powder effectively worked on reducing sugar levels with no undesirable side effects, hence it is an effective remedy and a therapeutic agent in lowering sugar level.

The polyherbal formulation made from *Gymnema sylvestre* (GSPF kwath; mixture of 10 herbs) exerted a significant curtailment of blood glucose (23.5 % and 26.7% for fasting and postprandial glucose level, respectively) and glycosylated hemoglobin (11.7%). 6 months of GSPF therapy reduce the serum cholesterol (14.4%), triglycerides (21.7%), LDL (26.8%) and VLDL (21.7%) levels. A marked increase was also recorded in the biochemical marker for oxidative stress (68). In an-

other study, the short-term supplementation of G-400, a polyherbal formulation (1000mg/day for 8 weeks) was used to attenuate the hyperglycemia and hyperlipidemia in the patients (69). Yadav et al. reviewed the preventive and therapeutic aspects of *Gymnema sylvestre* as a potential herbal drug in type 2 diabetes (70).

Other Therapeutic Activates of *Gymnema sylvestre*

The *Gymnema sylvestre* has proved to possess several other therapeutic activities. Various parts of the plant though pungent act as a tonic for liver, vomiting causative, promote the production of urine, refrigerant, astringent, heal, treatment of anomalies in liver and spleen, gas, acidity, constipation, jaundice, helminthiasis and abnormal menstruation.

Antimicrobial Activity

In vitro, antibiotic activity of *Gymnema sylvestre* extracted with petroleum ether then with chloroform and lastly with a mixture of water: Ethanol (1:1) was effective to inhibit *Bacillus subtilis*, *Staphylococcus aureus* but not *Escherichia coli* (71). The hexane extract of *Gymnema sylvestre* also showed maximum inhibition against *Serratia marcescens* (MTCC 86) (72). The ethanol-based excerpt of the leaves of *Gymnema sylvestre* have exhibited microbicidal potential against *Bacillus pumilis*, *Bacillus subtilis*, *Pseudomonas aeruginosa* and *Staphylococcus aureus* and but was ineffective in case of *Proteus vulgaris* and *Escherichia coli* (17). The bioactive molecule, Gymnemic acid is also used as an antifungal agent as it inhibits the *Candida albican* from yeast to hyphal transition which is a key virulence factor (73).

Anticancer Activity

The efficacy of chloroform, ethyl acetate and alcoholic extracts of *Gymnema sylvestre* were tested on A549 (human lung cancer) cell lines and MCF7 (human breast cancer) cell lines *in vitro* by MTT Assay (74). At 50 and 100 $\mu\text{g/ml}$ concentration, the extracts positively affect the MCF 7 cell lines while the activity was dose-dependent with similar IC_{50} values their efficacy on the A549 cells was trivial. However, the effectiveness of chloroform and ethyl acetate excerpts was better when compared to that of the alcoholic extract

on the A549 cell lines. The anticancer activity may be due to the gymnemic acids. The cytotoxic activity of isolated saponin, gymnemagol from leaves was tested on HeLa cells and reported to be a good cytotoxic agent (63%) (75). The green synthesis of silver and gold nanoparticle from *Gymnema sylvestre* showed cytotoxic activity against Hep2 cells with the IC₅₀ value of 121 µg/ml for silver nanoparticle and 38% inhibition for gold nanoparticle at a concentration of 250 µg/ml. However, silver nanoparticles of *Gymnema sylvestre* proved much better for their antiproliferative effects in Hep2 cells which were mediated through induction of apoptosis (76). The gold nanoparticle of *Gymnema sylvestre* was also synthesized by Arunchalam et al. (15) evaluated against HT29 and Vero cell lines at different concentration. It was observed that the gold nanoparticles were more sensitive toward human cancer cell line (HT29) as compared to Vero cell line.

Anti-Arthritic Activity

The leaf extracts of *Gymnema sylvestre* is has been utilized for demonstrating the anti-arthritic activity in albino rats. The anti-arthritic action of petroleum ether extract and aqueous extract was studied in Freund's adjuvant-induced arthritis in rats (19). The presence of steroids, triterpenoids and saponin glycosides in the leaves *Gymnema sylvestre* leads to the potential anti-arthritic activity. The petroleum ether extract treated groups exhibited significantly reduced paw swelling by blocking the inflammatory cells (77).

Toxicological Evaluation of *Gymnema sylvestre*

Even in the long-term study, there was no report of any undesirable effect. However, hypoglycemia is one of the possibilities of its administration.

High doses of *Gymnema sylvestre* leaves did not exhibit any adverse effect on the gastrointestinal mucosa; hence, it poses to be a harmless gastrotoxic anti-inflammatory response compared with other anti-inflammatory agents (78). While in an acute toxicity investigation in mice a negative behavioral changes, neurologic and autonomic upshots were evident. Safety ratio (LD50/ED50) in the diabetics was sixteen while in the healthy rats it was eleven (79).

Evidence regarding the toxicity of the plant or its parts on the human has been documented rather in patients with quotidian consumption of *Gymnema sylvestre* the serum urea, uric acid, and hemoglobin levels remain normal. However, it is suggested to avoid the administration of *Gymnema sylvestre* during pregnancy. Thus, *Gymnema sylvestre* is generally safe and devoid of side effect. The administration is recommended under the clinical supervision of the healthcare professional.

Future Perspectives of Herbal Drug and its Challenges

The use of plants and their parts for the effective healing of any ailment has been the fulcrum of the investigation. It is estimated that nearly 70% of the drugs used in India are derived from plants. Its efficacy has mounted its marketability with a twelve-monthly growth of 5% and 15%. The gross global herbal market of US \$ 62 billion approximately may exponentially sprout to US \$ 5 trillion by 2050. Ayurveda contributes Rs. 3500 crores (US \$ 813 million) annually to international market (80).

Gymnema sylvestre is a magical herb effective for combating a wide range of health conditions. Every part of the plant has been attributed with medicinal values which have been immensely exploited for the same. Various herbal products based on *Gymnema sylvestre* are formulated and sold in the market. Several brands of extracts, tablets and herbal tea are based on this herb. There are various products of *Gymnema*, viz. *Gymnema* 4G (M1320/M1325), *Gymnema sylvestre* 75, *Gymnema* tea are now regularly used in the day today life.

As with any type of herbal supplement, safety and strength of the formulation are not clinically proven. Thus, taking a note of the intake dose is imperative to minimize the risk of *Gymnema sylvestre* side effects. No established and safe methodology is available for the product eminence and effectiveness. The improvement and materialistic functionality of herbal medicine industries are largely reliant upon its accessibility to amenities and in a row concerning the isolation, refining, and advertisement the industrial potential of plants. Therefore, a systematic investigation is mandated to develop drugs based on the components of *Gymnema sylvestre*. An ef-

Illustration of the bioactive compounds isolated from different parts of *Gymnema sylvestre*

Bioactive compounds	Part used	Extraction	Study results	Model used to induce diabetes	Beneficial role	References
Conduritol	Stem	Ethanol	Exhibited antidiabetic activity by elevating thymus, pancreas, splenic index or inhibiting the atrophy of thymus, pancreas, splenic of diabetic rat	Diabetic rats induced by alloxan	Antidiabetic activity	(81)
Dihydroxy gymnemic triacetate	Leaves	Acetone	Acquire the hypoglycemic and antihyperlipidemic activity in streptozotocin-induced diabetic rats	Streptozotocin-induced diabetic rats	Hypoglycemic and antihyperlipidemic	(44)
Gymnemic acids I-IV and gymnemasaponin V	Leaves	Methanol extract	Gymnemic acid IV treatment decrease glucose uptake and blood glucose level, Increase plasma insulin	Streptozotocin-induced diabetic mice.	Anti-obese and antihyperglycemic pro-drug.	(82)
Deacyl gymnemic acid	Leaves		Administration of deacyl gymnemic acid reduced the blood pressure and improved fasting sugar level. A decrease in HOMA-IR with fair improvement in lipid profile was observed.	High fructose diet for 20 days to induce metabolic syndrome in a rat model	Deacyl gymnemic acid alleviates the insulin resistance a rat model of metabolic syndrome.	(83)
Gymnemat (GA), a mixture of triterpene of glucuronides	Leaves	Water extract	Gymnemat treatment improved the lipid profiles, total cholesterol was decreased about 1/3, LDL, VLDL decreased about 1/2. The ratio of HDL-C to the total cholesterol was increased. The serum triglyceride was decreased to the 1/4 of OLETF control.	Genetic multifactor syndrome animal (OLETF rat)	Administration with gymnemat promoted weight loss was due to the anti-lipidemic action	(84)
Saponin rich gymnema. sylvestre	Leaves	Water extract	Lowers body weight and organ weights. Moreover, Plasma TC, TG, VLDL, LDL-C were also reduced.	High fat diet induced wistar rats	Saponin rich <i>Gymnema sylvestre</i> R.Br aqueous leaf extract can be used for obesity treatment.	(85)
Gymnemagenin and gymnemic acids	Leaves	Ethanol extract	A decrease in the blood glucose, serum TG, LDL, TC. Increase in serum insulin and antioxidant enzymes such as glutathione, catalase, and reduced glutathione was reported.	Sprague-Dawley rats	Increase in the antioxidant level and lowering lipid peroxidation	(86)
GS3, and GS4	Leaves	Alcoholic extract	Raise the serum insulin to levels closer to normal fasting levels. diabetic rat pancreas, Treatment with both GS ₃ , and GS ₄ , compound were able to double the islet number and β cell number	Streptozotocin treated rats	Probably due to repair/regeneration of the endocrine pancreas	(87)
Triterpene glycoside Glycoside	Leaves	90 % alcohol	Decrease the blood glucose ($p < 0.05$) at 2 and 4 hr after glucose load in the glucose tolerance test.	Streptozotocin induced diabetic rats	Hypoglycemic activity in control and streptozotocin induced diabetic rats.	(88)
Gymnemoside b	Leaves	Methanol extract	Gymnemoside b produced some inhibitory activity on glucose absorption after oral glucose loading in rats.	Male Wistar rat	Inhibitory activity on glucose absorption	(89)

Abbreviation: HOMA-IR, (homeostatis model assessment- insulin resistance; OLETF rat, Otsuka Long Evans Tokushima Fatty; LDL, low density lipoprotein VLDL, very low density lipoprotein; HDL-C, high density lipoprotein; GS, *Gymnema sylvestre*

fective and safe drug can be flourished after an extensive clinical investigation which would be effective, natural, pharmacologically non-toxic and pristine.

Conclusions

Diabetes mellitus is the most common metabolic disorder affecting human beings and is characterized by chronic hyperglycemia. The prevalence of diabetes is rising and aggravating all over the world is being associated with an increase in financial burden, a decrease in quality of life, morbidity and mortality. In the past few years, *Gymnema sylvestre* has emerged as a cost-effective and potential intervention by targeting the etiological factors connected with diabetes. It functions as a blood sugar lowering agent, insulin stimulator, β -cell regenerator, facilitator of anti-obesity and an anti-inflammatory agent. It produces not only blood glucose homeostasis but also showed anti-cancerous, anti-microbial, anti-arthritic activities.

Gymnema sylvestre holds a definite promise in the management of diabetes mellitus. This review has updated the pharmacological, toxicological and clinical evaluation of this plant for treatment of diabetes and its associated abnormalities. The ethnomedical approach for diabetes using *Gymnema sylvestre* is practical, logical and economically worthwhile. But still, it requires scientific and technological validation, standardization for justification of its wide acceptability among a modern system of medicine. One can look toward to an integrated approach to future medicine using this traditional drug.

Acknowledgments

This work was supported by the Research Grant from Pukyong National University (2017).

References

- Shelar DB, Shirote PJ. Natural product in drug discovery: back to future. *J Pharm Res* 2010; 3: 2007-8.
- Kala CP, Farooquee NA, Dhar U. Prioritization of medicinal plants on the basis of available knowledge, existing practices and use value status in Uttaranchal, India. *Biodivers Conserv* 2004; 13: 453-69.
- Shah D, Agarawal V, Parikh R. Noninvasive insulin delivery system: a review. *Int J Appl Pharm* 2010; 2: 35-40.
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; 27: 1047-53.
- Pham HTT, Hoang MC, Ha TKQ et al. Discrimination of different geographic varieties of *Gymnema sylvestre*, an anti-sweet plant used for the treatment of type 2 diabetes. *Phytochemistry* 2018; 150: 12-22.
- Yadav D, Tiwari A, Mishra M et al. Anti-hyperglycemic and anti-hyperlipidemic potential of a polyherbal preparation "Diabegon" in metabolic syndrome subject with type 2 diabetes. *Afr J Tradit Complement Altern Med* 2014; 11: 249-56.
- Singh SP, Patra CN, Dinda SC. A comparative evaluation of the flow and compaction characteristics of *Gymnema sylvestre* leaf powder. *J Adv Pharm Res* 2010; 1: 1-11.
- Hajare R. Comparing Modified and Relationship Study of *Gymnema Sylvestre* Against Diabetes. *SF J Pub Health* 2018; 2.
- Smruthi G, Mahadevan V, Sahayam S, Rajalakshmi P, Vadi-vel V, Brindha P. Anti-Diabetic Potential of Selected Indian Traditional Medicinal Plants-An Updated Review. *Journal of Pharmaceutical Sciences and Research* 2016; 8: 1144.
- Ekka NR, Dixit VK. Ethno-pharmacognostical studies of medicinal plants of jashpur district (Chhattisgarh). *Int J Green Pharm* 2007; 1.
- Meena AK, Bansal P, Kumar S. Plants-herbal wealth as a potential source of ayurvedic drugs. *Asian J Tradit Med* 2009; 4: 152-70.
- Rachh PR, Rachh MR, Ghadiya NR et al. Antihyperlipidemic activity of *Gymnema sylvestre* R. Br. leaf extract on rats fed with high cholesterol diet. *Int J Pharmacol* 2010; 6: 138-41.
- Manish K, Aditi K, Renu A, Gajraj S, Poonam M. Antiobesity property of hexane extract from the leaves of *Gymnema sylvestre* in high fed cafeteria diet induced obesity rats. *International Research Journal of Pharmacy* 2011; 2: 112-6.
- Rachh PR, Patel SR, Hirpara HV et al. In vitro evaluation of antioxidant activity of *Gymnema sylvestre* r. br. leaf extract. *Romanian J Biology Plant Biol* 2009; 54: 141-8.
- Arunachalam KD, Arun LB, Annamalai SK, Arunachalam AM. Potential anticancer properties of bioactive compounds of *Gymnema sylvestre* and its biofunctionalized silver nanoparticles. *Int J Nanomedicine* 2015; 10: 31.
- Malik JK, Manvi FV, Nanjwade BK, Alagawadi KR, Sinsh S. Immunomodulatory activity of *Gymnema sylvestre* R. Br. leaves on in vitro human neutrophils. *J Pharm Res* 2009; 2: 1284-6.
- Satdive RK, Abhilash P, Fulzele DP. Antimicrobial activity of *Gymnema sylvestre* leaf extract. *Fitoterapia* 2003; 74: 699-701.
- Meyer JS. Diabetes and wound healing. *Crit Care Nurs Clin North Am* 1996; 8: 195-201.

19. Malik JK, Manvi FV, Nanjware BR, Dwivedi DK, Purohit P, Chouhan S. Anti-arthritic activity of leaves of *Gymnema sylvestre* R. Br. leaves in rats. *Pharm Lett* 2010; 2: 336-41.
20. Gupta SS, Seth CB. Experimental studies on pituitary diabetes. II. Comparison of blood sugar level in normal and anterior pituitary extract-induced hyperglycaemic rats treated with a few Ayurvedic remedies. *Indian J Med Res* 1962; 50: 708.
21. Porchezian E, Dobriyal RM. An overview on the advances of *Gymnema sylvestre*: chemistry, pharmacology and patents. *Pharmazie* 2003; 58: 5-12.
22. Shanmugasundaram KR, Panneerselvam C, Samudram P, Shanmugasundaram ERB. Enzyme changes and glucose utilisation in diabetic rabbits: the effect of *Gymnema sylvestre*, R. Br. *J Ethnopharmacol* 1983; 7: 205-34.
23. Shanmugasundaram ERB, Venkatasubrahmanyam M, Vijendran N, Shanmugasundaram KR. Effect of an isolate from *Gymnema sylvestre*, R. Br. in the control of diabetes mellitus and the associated pathological changes. *Anc Sci Life* 1988; 7: 183.
24. Srivastava Y, Nigam SK, Bhatt HV, Verma Y, Prem AS. Hypoglycemic and life-prolonging properties of *Gymnema sylvestre* leaf extract in diabetic rats. *Isr J Med Sci* 1985; 21: 540.
25. Shanmugasundaram KR, Panneerselvam C, Samudram P, Shanmugasundaram E. The insulinotropic activity of *Gymnema sylvestre*, R. Br. An Indian medical herb used in controlling diabetes mellitus. *Pharmacol Res Commun* 1981; 13: 475-86.
26. Shanmugasundaram ERB, Gopinath KL, Shanmugasundaram KR, Rajendran VM. Possible regeneration of the islets of Langerhans in streptozotocin-diabetic rats given *Gymnema sylvestre* leaf extracts. *J Ethnopharmacol* 1990; 30: 265-79.
27. Persaud SJ, Al-Majed H, Raman A, Jones PM. *Gymnema sylvestre* stimulates insulin release in vitro by increased membrane permeability. *J Endocrinol* 1999; 163: 207-12.
28. Sheoran S, Panda BP, Admane PS, Panda AK, Wajid S. Ultrasound-assisted extraction of gymnemic acids from *Gymnema sylvestre* leaves and its effect on insulin-producing RINm-5 F β cell lines. *Phytochem Anal* 2015; 26: 97-104.
29. Liu B, Asare-Anane H, Al-Romaiyan A et al. Characterisation of the insulinotropic activity of an aqueous extract of *Gymnema sylvestre* in mouse β -cells and human islets of Langerhans. *Cell Physiol Biochem* 2009; 23: 125-32.
30. Ahmed ABA, Rao AS, Rao MV. In vitro callus and in vivo leaf extract of *Gymnema sylvestre* stimulate β -cells regeneration and anti-diabetic activity in Wistar rats. *Phytomedicine* 2010; 17: 1033-9.
31. Sujin RM. Anti-diabetic effect of *Gymnema sylvestre* (asclepiadaceae) powder in the stomach of rats. *Ethnobot Leaflet* 2008; 2008: 153.
32. Imoto T, Miyasaka A, Ishima R, Akasaka K. A novel peptide isolated from the leaves of *Gymnema sylvestre*—I. Characterization and its suppressive effect on the neural responses to sweet taste stimuli in the rat. *Comp Biochem Physiol A Comp Physiol* 1991; 100: 309-14.
33. Shigemura N, Nakao K, Yasuo T et al. Gurmarin sensitivity of sweet taste responses is associated with co-expression patterns of T1r2, T1r3, and gustducin. *Biochem Biophys Res Commun* 2008; 367: 356-63.
34. Miyasaka A, Imoto T. Electrophysiological characterization of the inhibitory effect of a novel peptide gurmarin on the sweet taste response in rats. *Brain Res* 1995; 676: 63-8.
35. Kamble B, Gupta A, Moothedath I et al. Effects of *Gymnema sylvestre* extract on the pharmacokinetics and pharmacodynamics of glimepiride in streptozotocin induced diabetic rats. *Chem Biol Interact* 2016; 245: 30-8.
36. Venkatachalam P, Thiyagarajan M, Sahi SV. Fabrication of bioactive molecules loaded chitosan nanoparticles using *Gymnema sylvestre* leaf extracts and its antidiabetic potential in experimental rat model. *J Bionanosci* 2015; 9: 363-72.
37. Yoshikawa K, Kondo Y, Arihara S, Matsuura K. Antisweet natural products. IX. Structures of gymnemic acids XV-XVIII from *Gymnema sylvestre* R. Br. V. *Chem Pharm Bull (Tokyo)* 1993; 41: 1730-2.
38. Ye WC, Zhang QW, Liu X, Che CT, Zhao SX. Oleanane saponins from *Gymnema sylvestre*. *Phytochemistry* 2000; 53: 893-9.
39. Yoshikawa K, Arihara S, Matsuura K, Miyaset T. Damarane saponins from *Gymnema sylvestre*. *Phytochemistry* 1992; 31: 237-41.
40. Murakami N, Murakami T, Kadoya M, Matsuda H, Yamahara J, Yoshikawa M. New hypoglycemic constituents in "gymnemic acid" form *Gymnema sylvestre*. *Chem Pharm Bull (Tokyo)* 1996; 44: 469-71.
41. Shenoy RS, Prashanth KVH, Manonmani HK. In Vitro Antidiabetic Effects of Isolated Triterpene Glycoside Fraction from *Gymnema sylvestre*. *Evid Based Complement Alternat Med* 2018; 2018: 7154702.
42. Bnouham M, Ziyat A, Mekhfi H, Tahri A, Legssyer A. Medicinal plants with potential antidiabetic activity—A review of ten years of herbal medicine research (1990-2000). *Int J Diabetes Metab* 2006; 14: 1.
43. Yoshikawa M, Murakami T, Matsuda H. Medicinal foodstuffs. X. Structures of new triterpene glycosides, gymnemosides-c, -d, -e, and -f, from the leaves of *Gymnema sylvestre* R. Br.: influence of gymnema glycosides on glucose uptake in rat small intestinal fragments. *Chem Pharm Bull (Tokyo)* 1997; 45: 2034-8.
44. Daisy P, Eliza J, Farook KAMM. A novel dihydroxy gymnemic triacetate isolated from *Gymnema sylvestre* possessing normoglycemic and hypolipidemic activity on STZ-induced diabetic rats. *J Ethnopharmacol* 2009; 126: 339-44.
45. Sugihara Y, Nojima H, Matsuda H, Murakami T, Yoshikawa M, Kimura I. Antihyperglycemic effects of gymnemic acid IV, a compound derived from *Gymnema sylvestre* leaves in streptozotocin-diabetic mice. *J Asian Nat Prod Res* 2000; 2: 321-7.
46. Rathore PK, Arathy V, Attimarad VS, Kumar P, Roy S. In-silico analysis of gymnemagenin from *Gymnema sylvestre* (Retz.) R. Br. with targets related to diabetes. *J Theor Biol* 2016; 391: 95-101.

47. Omae T, Shimamoto C, Hiraike Y et al. Hyperlipidemia and fat absorption in model rats with type 2 diabetes mellitus. *Bull Osaka Med Coll* 2006; 52: 45-58.
48. Bishayee A, Chatterjee M. Hypolipidaemic and antiatherosclerotic effects of oral *Gymnema sylvestre* R. Br. Leaf extract in albino rats fed on a high fat diet. *Phytother Res* 1994; 8: 118-20.
49. Mall GK, Mishra PK, Prakash V. Antidiabetic and hypolipidemic activity of *Gymnema sylvestre* in alloxan induced diabetic rats. *Global J Biotechnol Biochem* 2009; 4: 37-42.
50. Osman M, Fayed SA, Ghada IM, Romeilah RM. Protective effects of chitosan, ascorbic acid and *Gymnema sylvestre* against hypercholesterolemia in male rats. *Aust J Basic Appl Sci* 2010; 4: 89-98.
51. Shigematsu N, Asano R, Shimosaka M, Okazaki M. Effect of administration with the extract of *Gymnema sylvestre* R. Br leaves on lipid metabolism in rats. *Biol Pharm Bull* 2001; 24: 713-7.
52. Stepan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. *Nature* 2001; 409: 307-12.
53. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule- β selectively impair insulin action on glucose production. *J Clin Invest* 2003; 111: 225-30.
54. Pravenec M, Kazdová L, Landa V et al. Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. *J Biol Chem* 2003; 278: 45209-15.
55. Nakamura Y, Tsumura Y, Tonogai Y, Shibata T. Fecal steroid excretion is increased in rats by oral administration of gymnemic acids contained in *Gymnema sylvestre* leaves. *J Nutr* 1999; 129: 1214-22.
56. Shigematsu N, Asano R, Shimosaka M, Okazaki M. Effect of long term-administration with *Gymnema sylvestre* R. BR on plasma and liver lipid in rats. *Biol Pharm Bull* 2001; 24: 643-9.
57. Preuss HG, Bagchi D, Bagchi M, Rao CVS, Satyanarayana S, Dey DK. Efficacy of a novel, natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX, niacin-bound chromium and *Gymnema sylvestre* extract in weight management in human volunteers: A pilot study. *Nutr Res* 2004; 24: 45-58.
58. Kaneto H, Kajimoto Y, Miyagawa J et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. *Diabetes* 1999; 48: 2398-406.
59. Moussa SA. Oxidative stress in diabetes mellitus. *Romanian J Biophys* 2008; 18: 225-36.
60. Rizvi AA. The role of inflammation in diabetes and its complications. *South Med J* 2006; 99: 8-10.
61. Singh VK, Dwivedi P, Chaudhary BR, Singh R. Immunomodulatory Effect of *Gymnema sylvestre* (R. Br.) Leaf Extract: An In Vitro Study in Rat Model. *PLoS One* 2015; 10: e0139631.
62. Kiranmai M, Kazim SM, Ibrahim M. Combined wound healing activity of *Gymnema sylvestre* and *Tagetes erecta* Linn. *Int J Pharm Appl* 2011; 1: 135-40.
63. Khare AK, Tondon RN, Tewari JP. Hypoglycaemic activity of an indigenous drug (*Gymnema sylvestre*, 'Gurmar') in normal and diabetic persons. *Indian J Physiol Pharmacol* 1983; 27: 257.
64. Joffe DJ, Freed SH. Effect of extended release *Gymnema sylvestre* leaf extract (Beta Fast GXR) alone or in combination with oral hypoglycemics or insulin regimens for type 1 and type 2 diabetes. *Diabetes Control Newslett* 2001; 76.
65. Baskaran K, Ahamath BK, Shanmugasundaram KR, Shanmugasundaram ERB. Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *J Ethnopharmacol* 1990; 30: 295-305.
66. Shanmugasundaram ERB, Rajeswari G, Baskaran K, Kumar BRR, Shanmugasundaram KR, Ahmath BK. Use of *Gymnema sylvestre* leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. *J Ethnopharmacol* 1990; 30: 281-94.
67. Paliwal R, Kathori S, Upadhyay B. Effect of Gurmar (*Gymnema sylvestre*) powder intervention on the blood glucose levels among diabetics. *Stud Ethno-Med* 2009; 3: 133-5.
68. Mahajan S, Chauhan P, Subramani SK et al. Evaluation of "GSPF kwath": A *Gymnema sylvestre*-containing polyherbal formulation for the treatment of human type 2 diabetes mellitus. *Eur J Integr Med* 2015; 7: 303-11.
69. Kurian GA, Manjusha V, Nair SS, Varghese T, Padikkala J. Short-term effect of G-400, polyherbal formulation in the management of hyperglycemia and hyperlipidemia conditions in patients with type 2 diabetes mellitus. *Nutrition* 2014; 30: 1158-64.
70. Yadav D, Cho K-H. Preventive and therapeutic aspects of selected herbal medicines in diabetes mellitus. *Progress in Nutrition* 2017; 19: 117-26.
71. Saumendu DR, Jeet K, Dipankar S, Singh TB, Prabha BA. In vitro antibiotic activity of various extracts of *Gymnema sylvestre*. *Int J Pharma Res Devel* 2010; 2.
72. Thalikkunnil ST, Sukesh K, Densingh J. Phytochemical investigation and antibacterial activity of *Gymnema sylvestre* and *Andrographis paniculata* from western ghats. *Phytomedicine* 2011; 3: 254.
73. VEDIYAPPAN G, Dumontet V, Pelissier F, d'Enfert C. Gymnemic acids inhibit hyphal growth and virulence in *Candida albicans*. *PLoS One* 2013; 8: e74189.
74. Jayachitra A, Muniyandi MJ. Pharmacological potential of *Gymnema sylvestre*: A review. *J Pharmacol Toxicol Investig* 2015; 1: 54-8.
75. Khanna V, Kannabiran K. Anticancer-cytotoxic activity of saponins isolated from the leaves of *Gymnema sylvestre* and *Eclipta prostrata* on HeLa cells. *Int J Green Pharm* 2009; 3: 227.
76. Nakkala JR, Mata R, Bhagat E, Sadras SR. Green synthesis of silver and gold nanoparticles from *Gymnema sylvestre* leaf extract: study of antioxidant and anticancer activities. *J Nanopart Res* 2015; 17: 151.
77. Eric G, Lawrence J. Rheumatoid arthritis and its therapy. *The textbook of therapeutics drug and disease management* Baltimore: Williams and Wilkins Company 1996: 579-95.

78. Diwan PV, Margaret I, Ramakrishna S. Influence of *Gymnema sylvestre* on inflammation. *Inflammopharmacology* 1995; 3: 271-7.
79. Chattopadhyay RR. A comparative evaluation of some blood sugar lowering agents of plant origin. *J Ethnopharmacol* 1999; 67: 367-72.
80. Joshi K, Chavan P, Warude D, Patwardhan B. Molecular markers in herbal drug technology. *Curr Sci* 2004; 87: 159-65.
81. Wei J, Zhen H, Qiu Q, Chen J, Zhou F. [Experimental [corrected] study of hypoglycemic activity of conduritol A of stems of *Gymnema sylvestre*]. *Zhongguo Zhong Yao Za Zhi*. 2008; 33: 2961-5.
82. Sugihara Y, Nojima H, Matsuda H, Murakami T, Yoshikawa M, Kimura I. Antihyperglycemic effects of gymnemic acid IV, a compound derived from *Gymnema sylvestre* leaves in streptozotocin-diabetic mice. *J Asian Nat Prod Res* 2000; 2: 321-7.
83. Bhansali S, Shafiq N, Pandhi P et al. Effect of a deacyl gymnemic acid on glucose homeostasis & metabolic parameters in a rat model of metabolic syndrome. *Indian J Med Res* 2013; 137: 1174.
84. Luo H, Kashiwagi A, Shibahara T, Yamada K. Decreased bodyweight without rebound and regulated lipoprotein metabolism by gymnemate in genetic multifactor syndrome animal. *Mol Cell Biochem* 2007; 299: 93-8.
85. Reddy RM. I, Vijaya T, Pushpa Latha B, Dattatreya Rao S. Saponins rich aqueous extract of *Gymnema sylvestre* R. Br reduces high fat diet induced obesity in wistar rats. *J Pharmacy Res* 2011; 4: 1237-9.
86. Kang M-H, Lee MS, Choi M-K, Min K-S, Shibamoto T. Hypoglycemic activity of *Gymnema sylvestre* extracts on oxidative stress and antioxidant status in diabetic rats. *J Agric Food Chem* 2012; 60: 2517-24.
87. Shanmugasundaram E, Gopinath KL, Shanmugasundaram KR, Rajendran V. Possible regeneration of the islets of Langerhans in streptozotocin-diabetic rats given *Gymnema sylvestre* leaf extracts. *J Ethnopharmacol* 1990; 30: 265-79.
88. Verma N, Shakya V, Saxena R. Antidiabetic activity of glycoside isolated from *Gymnema sylvestre* in streptozotocin induced diabetic rats. *Asian J Chem* 2008; 20: 5033.
89. Yoshikawa M, Murakami T, Kadoya M et al. Medicinal foodstuffs. IX. The inhibitors of glucose absorption from the leaves of *Gymnema sylvestre* R. BR. (Asclepiadaceae): structures of gymnemosides a and b. *Chem Pharm Bull (Tokyo)* 1997; 45: 1671-6.

Correspondence:

Prof. Minseok Kwak
Department of Chemistry, Pukyong National University, Busan, 48513, Republic of Korea
Tel: +82-51-629-5595
Fax: +82-51-629-5583
E-mail: mkwak@pukyong.ac.kr

Prof. Jun-O Jin
Department of Medical Biotechnology, Yeungnam University, Gyeongsan, 712-749, Republic of Korea
Tel: +82-53-810-3033
Fax: +82-53-810-4769
E-mail: jinjo@yu.ac.kr